3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Completed
1
Sponsor Class
OTHER
1
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Plasma cell
1
Other hematologic neoplasm
1
Lymphoid
1
Dermatologic
1
Conditions
Lymphoma, T-Cell, Peripheral
4
Lymphoma, T-Cell
4
Lymphoma, Large-Cell, Anaplastic
3
Recurrence
2
Multiple Myeloma
2
Lymphoma, Follicular
2
Immunoblastic Lymphadenopathy
2
Esophageal Squamous Cell Carcinoma
2
Adenocarcinoma Of Esophagus
2
Waldenstrom Macroglobulinemia
1
Unspecified Adult Solid Tumor, Protocol Specific
1
Subcutaneous panniculitis-like T-cell lymphoma
1
Stomach Neoplasms
1
Ovarian Neoplasms
1
Mycosis Fungoides
1
Lymphoma, T-Cell, Cutaneous
1
Lymphoma, Non-Hodgkin
1
Lymphoma, Mantle-Cell
1
Lymphoma, Large B-Cell, Diffuse
1
Lymphoma, B-Cell, Marginal Zone
1
Lymphoma
1
Lung Neoplasms
1
Leukemia, Lymphocytic, Chronic, B-Cell
1
Hodgkin Disease
1
Head and Neck Neoplasms
1
Fallopian Tube Neoplasms
1
Esophageal Neoplasms
1
Enteropathy-Associated T-Cell Lymphoma
1
Carcinoma, Non-Small-Cell Lung
1
Burkitt Lymphoma
1
Interventions
Rituximab
165
Cyclophosphamide
163
fludarabine phosphate
95
Peripheral Blood Stem Cell Transplantation
88
Filgrastim
72
Etoposide
65
Mycophenolic Acid
63
Whole-Body Irradiation
62
Cytarabine
59
Cyclosporine
53
Melphalan
52
Tacrolimus
47
Busulfan
43
Radiotherapy
42
Lenalidomide
42
Bortezomib
40
ibrutinib
39
fludarabine
39
Methotrexate
38
Antilymphocyte Serum
38
Carmustine
37
Bendamustine Hydrochloride
35
Vincristine
33
Doxorubicin
32
Dexamethasone
32
Granulocyte Colony-Stimulating Factor
29
Prednisone
26
Cord Blood Stem Cell Transplantation
25
venetoclax
22
obinutuzumab
22
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Lymphoma, Mantle-Cell
×
10-propargyl-10-deazaaminopterin
×
Clear all
NCT01947140
2022-11-23
PDX+Romi
Columbia University
Phase 1/2
Completed
57 enrolled